Replies to post #813928 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

High-Ranking Officer e❌,

Thanks for your x-cellent x-planation 😶

Both the U.K. & U.S. have announced initiatives to modernize clinical trial guidelines to speed innovation & streamline regulatory processes. The regulatory environment is highly relevant to NWBO & all other biotech companies …

“not enrolled a single patient in a trial in over 10 years“

Following initial commercialization, a biotech company becomes much more likely to sponsor & fund trials because R&D is costly. Over the past recent years, NWBO did not need to sponsor trials run by academic institutions & funded by peer-reviewed grants awarded by 🇺🇸U.S. NIH-NCI & the 🇺🇸U.S. DoD.

Fact ✅️: NWBO’s IP portfolio includes more than one pipeline product in active clinical development. There is an active DCVax-L Combo PII at UCLA today, & the aDC1 platform that NWBO licensed from Roswell Park in New York has also reached PII in combo with Merck’s pembrolizumab. NEXT GEN COMBOS will make some significant waves going forward!

This Roswell PII clinical trial is one example that just posted an update on Dec 30th. Moffitt is included on its list of trial sites, & it’s funded by a peer-reviewed grant awarded by the 🇺🇸U.S. DoD:

ASCO 2025

Targeted COMBO therapy regimens represent NEW innovations, & Roswell’s aDC1 technology is relatively new as a combo agent in clinical trials.

Dr. Kalinski



Merck is only one example, but the industry overall is trending toward combo research to enhance efficacy & reduce toxicity for patients.



Next Generation Dendritic Cell Treatments

AACR IMMUNO-ONCOLOGY CONFERENCE 2026




CA Institute for Immunology & Immunotherapy

Lifetime Achievement Award in Medicine

Pitt BioForge

Roswell Park Dendritic Cell Technology & IP

AI Fact-Checking




















AI Fact-Checking